Wall Street Analysts Predict an 85% Upside in Coherus BioSciences (CHRS): Here's What You Should Know

This article was originally published on Nasdaq

Shares of Coherus BioSciences (CHRS) have gained 17.3% over the past four weeks to close the last trading session at $10.02, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the pric

Responses